# Study of the Efficacy and Safety of Quetiapine Fumarate Extended Release (Seroquel XR)

> **NCT00779506** · PHASE4 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 96 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Quetiapine Fumarate XR

## Key facts

- **NCT ID:** NCT00779506
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** 2009-07
- **Final completion:** 2009-07
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2011-11-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00779506

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00779506, "Study of the Efficacy and Safety of Quetiapine Fumarate Extended Release (Seroquel XR)". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00779506. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*